Anemia, a prevalent hematological disorder, manifests as a decrease in the number of red blood cells (RBCs) or a reduction in hemoglobin levels. Its multifactorial etiologies, coupled with its varied clinical presentations, make the diagnostic approach to anemia complex and challenging. This article aims to elucidate a comprehensive approach to diagnosing anemia for healthcare professionals.
An initial evaluation should include a thorough history and physical examination. Key components include dietary habits, family history, and symptoms such as fatigue, pallor, and dyspnea. Physical findings like jaundice, glossitis, or koilonychia may point to specific types of anemia.
Complete blood count (CBC) is the cornerstone of anemia diagnosis. Anemia is classified as microcytic, normocytic, or macrocytic based on mean corpuscular volume (MCV). Other essential tests include peripheral smear, reticulocyte count, and serum iron studies.
Microcytic anemia is often due to iron deficiency or thalassemia, while macrocytic anemia may indicate vitamin B12 or folate deficiency, or myelodysplastic syndrome. Normocytic anemia requires further investigation, including evaluation for hemolysis or bone marrow disorders. A high reticulocyte count suggests increased RBC production, while a low count indicates decreased production or ineffective erythropoiesis.
If initial investigations are inconclusive, additional tests such as bone marrow biopsy, hemoglobin electrophoresis, or genetic testing may be warranted. The choice of further tests depends on the clinical context and the likelihood of specific diagnoses.
Diagnosing anemia requires a systematic approach, incorporating clinical evaluation, laboratory investigations, and interpretation of findings. Understanding the complexities of anemia and its diverse etiologies is crucial for healthcare professionals to ensure appropriate diagnosis and management. Further research is needed to refine diagnostic algorithms and enhance patient care.
1.
Year in Review: Non-Small Cell Lung Cancer
2.
Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat
3.
The need for more Latinx participants in Alzheimer's trials is urgent.
4.
Why palliative care goes hand in hand with treatment for people with cancer: Q&A
5.
MRD-Guided Azacitidine May Delay Relapse in AML, MDS
1.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
2.
The Danger of Methemoglobinemia and How to Prevent It
3.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
4.
Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain
5.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Thromboprophylaxis In Medical Settings
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation